Evidence map›Paper›PMID 33152031›Full record

ArticlePloS one2020

RNase H-dependent PCR enables highly specific amplification of antibody variable domains from single B-cells.

John Crissman, Yuhao Lin, Kevin Separa, Madeleine Duquette, Michael Cohen, Candyd Velasquez, Thomas Cujec

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

John CrissmanDepartment of Biologics Automation and High-Throughput Technologies, Eli Lilly and Company Biotechnology Center, San Diego, California, United States of America.
Yuhao LinDepartment of Biologics IT, Eli Lilly and Company Biotechnology Center, San Diego, California, United States of America.
Kevin SeparaDepartment of Biologics Automation and High-Throughput Technologies, Eli Lilly and Company Biotechnology Center, San Diego, California, United States of America.
Madeleine DuquetteDepartment of Biologics Automation and High-Throughput Technologies, Eli Lilly and Company Biotechnology Center, San Diego, California, United States of America.
Michael CohenDepartment of Biologics Automation and High-Throughput Technologies, Eli Lilly and Company Biotechnology Center, San Diego, California, United States of America.
Candyd VelasquezDepartment of Biologics Automation and High-Throughput Technologies, Eli Lilly and Company Biotechnology Center, San Diego, California, United States of America.
Thomas CujecDepartment of Biologics Automation and High-Throughput Technologies, Eli Lilly and Company Biotechnology Center, San Diego, California, United States of America.ORCID 0000-0002-6582-7848
Eli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunization-based antibody discovery platforms require robust and effective protocols for the amplification, cloning, expression, and screening of antibodies from large numbers of B-cells in order to effectively capture the diversity of an experienced Ig-repertoire. Multiplex PCR using a series of forward and reverse primers designed to recover antibodies from a range of different germline sequences is challenging because primer design requires the recovery of full length antibody sequences, low starting template concentrations, and the need for all the primers to function under the same PCR conditions. Here we demonstrate several advantages to incorporating RNase H2-dependent PCR (rh-PCR) into a high-throughput, antibody-discovery platform. Firstly, rh-PCR eliminated primer dimer synthesis to below detectable levels, thereby eliminating clones with a false positive antibody titer. Secondly, by increasing the specificity of PCR, the rh-PCR primers increased the recovery of cognate antibody variable regions from single B-cells, as well as downstream recombinant antibody titers. Finally, we demonstrate that rh-PCR primers provide a more homogeneous sample pool and greater sequence quality in a Next Generation Sequencing-based approach to obtaining DNA sequence information from large numbers of cloned antibody cognate pairs. Furthermore, the higher specificity of the rh-PCR primers allowed for a better match between native antibody germline sequences and the VL/VH fragments amplified from single B-cells.

Indexed as

AnimalsB-LymphocytesCHO CellsCricetulusDNA PrimersHigh-Throughput Nucleotide SequencingImmunoglobulin Variable RegionMiceMultiplex Polymerase Chain ReactionRibonuclease HSensitivity and SpecificitySingle-Cell AnalysisVaccinationDNA PrimersImmunoglobulin Variable RegionRibonuclease H

Identifiers

PMID33152031
PMCPMC7643965
OpenAlexW3096712951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.